Bristol Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib to treat moderate to severe plaque psoriasis.
The US drugmaker could face a long wait for a decision in the case of its US application, with the FDA assigning a Prescription Drug User Fee Act (PDUFA) goal date of September 10, 2022.
"Many remain undertreated or even untreated"These latest regulatory milestones are in addition to the NDA acceptance by Japan's Ministry of Health, Labor and Welfare for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze